Latest Articles
Latest
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
NEW! Beigene Sonrotoclax Clinical Trial
Accelerate the CureNew Clinical Trials for 2025!Headlines abound... ONE—"Use of BCL2 inhibitors has the potential to alter practice in the treatment of Waldenstrom's macroglobulinemia". IWMF Board Advisor, Professor Shirley D' Sa, of University College London...
VIDEO: Fitness Essentials for WM with Mark Wild
VIDEO NOW AVAILABLE!Exercise can feel overwhelming, especially with a cancer diagnosis. Symptoms like peripheral neuropathy and fatigue add to this challenge. Join Mark Wild, an award-winning cancer rehab expert and exercise coach. Learn about his thoughtful exercise...
The Next Big Thing? Protein BTK Degraders
We are encouraged and excited to share ground-breaking news from Nurix Therapeutics, a pharmaceutical partner in WM-NET, our growing network of 22 US research institutions coordinating Waldenstrom's macroglobulinemia (WM) clinical trials, supported by Accelerate the...
2025 IWMF Ed Forum Speakers Announced
We’re excited to announce the great lineup of speakers for the 2025 Educational Forum! If you support the Accelerate the Cure Campaign, this is the event for you. Attending an IWMF Ed Forum shows IWMF's unique strength in building community while focusing on cancer...
Registration Now Open! The 2025 European Educational Forum
Join us for the 2025 European Educational Forum on Wednesday, May 21st, in Chantilly, France!We’re excited to partner with Waldenström France to bring you an exclusive opportunity to connect with over 80 world-leading experts in WM, thanks to our collaboration with...
VIDEO: Whole Person Cancer Care: Living Well with WM
Whole person cancer care involves learning what matters most to patients and engaging them in health and wellness behaviors that influence their quality of life and longevity as the cancer is treated. Such care explicitly addresses mind-body-behavior-social and...
Subscribe Today!
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean scelerisque suscipit condimentum. Vestibulum in scelerisque eros. Fusce sed massa vel sem commodo.
Featured Story
Lorem ipsum dolor sit consectetur adipiscing elit.
Proin eget tortor risus. Praesent sapien massa, convallis a pellentesque nec, egestas non nisi. Curabitur aliquet quam id dui posuere blandit. Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Sed porttitor lectus nibh. Cras ultricies ligula sed magna dictum porta. Proin eget tortor risus. Curabitur non nulla sit amet nisl tempus convallis quis ac lectus. Nulla quis lorem ut libero malesuada feugiat.
Pellentesque in ipsum id orci porta dapibus. Nulla porttitor accumsan tincidunt. Nulla quis lorem ut libero malesuada feugiat. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Donec velit neque, auctor sit amet aliquam vel, ullamcorper sit amet ligula. Vivamus suscipit tortor eget felis porttitor volutpat. Proin eget tortor risus. Cras ultricies ligula sed magna dictum porta. Proin eget tortor risus. Vivamus suscipit tortor eget felis porttitor volutpat.
Featured Author
Vestibulum Malesuada Non Magna Lacinia
Proin eget tortor risus. Praesent sapien massa, convallis a pellentesque nec, egestas no
Staff Picks
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
NEW! Beigene Sonrotoclax Clinical Trial
Accelerate the CureNew Clinical Trials for 2025!Headlines abound... ONE—"Use of BCL2 inhibitors has the potential to alter practice in the treatment of Waldenstrom's macroglobulinemia". IWMF Board Advisor, Professor Shirley D' Sa, of University College London...
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
NEW! Beigene Sonrotoclax Clinical Trial
Accelerate the CureNew Clinical Trials for 2025!Headlines abound... ONE—"Use of BCL2 inhibitors has the potential to alter practice in the treatment of Waldenstrom's macroglobulinemia". IWMF Board Advisor, Professor Shirley D' Sa, of University College London...
VIDEO: Fitness Essentials for WM with Mark Wild
VIDEO NOW AVAILABLE!Exercise can feel overwhelming, especially with a cancer diagnosis. Symptoms like peripheral neuropathy and fatigue add to this challenge. Join Mark Wild, an award-winning cancer rehab expert and exercise coach. Learn about his thoughtful exercise...
The Next Big Thing? Protein BTK Degraders
We are encouraged and excited to share ground-breaking news from Nurix Therapeutics, a pharmaceutical partner in WM-NET, our growing network of 22 US research institutions coordinating Waldenstrom's macroglobulinemia (WM) clinical trials, supported by Accelerate the...
2025 IWMF Ed Forum Speakers Announced
We’re excited to announce the great lineup of speakers for the 2025 Educational Forum! If you support the Accelerate the Cure Campaign, this is the event for you. Attending an IWMF Ed Forum shows IWMF's unique strength in building community while focusing on cancer...
Popular Categories
Categories
Gadgets & Devices
Fashion
Travel
Trending Now
Hot
Latest Trending
Featured Trending
Staff Picks
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
NEW! Beigene Sonrotoclax Clinical Trial
Accelerate the CureNew Clinical Trials for 2025!Headlines abound... ONE—"Use of BCL2 inhibitors has the potential to alter practice in the treatment of Waldenstrom's macroglobulinemia". IWMF Board Advisor, Professor Shirley D' Sa, of University College London...
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
NEW! Beigene Sonrotoclax Clinical Trial
Accelerate the CureNew Clinical Trials for 2025!Headlines abound... ONE—"Use of BCL2 inhibitors has the potential to alter practice in the treatment of Waldenstrom's macroglobulinemia". IWMF Board Advisor, Professor Shirley D' Sa, of University College London...
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
NEW! Beigene Sonrotoclax Clinical Trial
Accelerate the CureNew Clinical Trials for 2025!Headlines abound... ONE—"Use of BCL2 inhibitors has the potential to alter practice in the treatment of Waldenstrom's macroglobulinemia". IWMF Board Advisor, Professor Shirley D' Sa, of University College London...
Vestibulum Malesuada Non Magna Lacinia
Home Office
Expansion of IMBRUVICA® (ibrutinib) Label in the U.S.
U.S. Food and Drug Administration (FDA) Approves a Label Expansion for IMBRUVICA® (ibrutinib) On February 26th, Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. Food and Drug...
NEW! Beigene Sonrotoclax Clinical Trial
Accelerate the CureNew Clinical Trials for 2025!Headlines abound... ONE—"Use of BCL2 inhibitors has the potential to alter practice in the treatment of Waldenstrom's macroglobulinemia". IWMF Board Advisor, Professor Shirley D' Sa, of University College London...
VIDEO: Fitness Essentials for WM with Mark Wild
VIDEO NOW AVAILABLE!Exercise can feel overwhelming, especially with a cancer diagnosis. Symptoms like peripheral neuropathy and fatigue add to this challenge. Join Mark Wild, an award-winning cancer rehab expert and exercise coach. Learn about his thoughtful exercise...
The Next Big Thing? Protein BTK Degraders
We are encouraged and excited to share ground-breaking news from Nurix Therapeutics, a pharmaceutical partner in WM-NET, our growing network of 22 US research institutions coordinating Waldenstrom's macroglobulinemia (WM) clinical trials, supported by Accelerate the...
2025 IWMF Ed Forum Speakers Announced
We’re excited to announce the great lineup of speakers for the 2025 Educational Forum! If you support the Accelerate the Cure Campaign, this is the event for you. Attending an IWMF Ed Forum shows IWMF's unique strength in building community while focusing on cancer...
Our Recommended Products
Shop
